A carregar...
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
The treatment of patients with myelodysplastic syndromes (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q deletion (del(5q)) with or without additional cytogenetic...
Na minha lista:
| Publicado no: | Ann Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4684154/ https://ncbi.nlm.nih.gov/pubmed/26504152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv488 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|